6998 Edding Genor Group Holdings Limited HKEX · China

Edding Genor Group Holdings (6998) news

Edding Genor Group Holdings Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 6998, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Edding Genor Group Holdings news

We have not published a story on Edding Genor Group Holdings yet. When there is news, it will appear here.

Questions about Edding Genor Group Holdings

What is the ticker symbol of Edding Genor Group Holdings?

Edding Genor Group Holdings Limited trades under the ticker 6998 on HKEX.

Where is Edding Genor Group Holdings listed?

Edding Genor Group Holdings Limited is listed on HKEX.

Which country or territory is Edding Genor Group Holdings listed under?

Our directory records Edding Genor Group Holdings Limited under China.

What does Edding Genor Group Holdings do?

Our directory classifies Edding Genor Group Holdings Limited as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Edding Genor Group Holdings?

The ISIN recorded for Edding Genor Group Holdings Limited is KYG3871A1004.

Does aibio.space cover Edding Genor Group Holdings?

aibio.space lists Edding Genor Group Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Edding Genor Group Holdings?

Companies in our directory listed in the same country and business area as Edding Genor Group Holdings: Kintor Pharmaceutical, Sinocelltech Group, Shenzhen Kangtai Biological Products Co., Medtide, Pacific Shuanglin Bio-pharmacy Co., Boji Medical Technology Co..

Investor discussion: Edding Genor Group Holdings

Members talk about Edding Genor Group Holdings (6998). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Edding Genor Group Holdings, newest first. Each line links the filing it comes from.

Jul 16, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN CANDID THERAPEUTICS, INC.. Source
Feb 3, 2026Listings
Share consolidation: CHANGE OF COMPANY NAME AND STOCK SHORT NAME. Source
Dec 29, 2025Mergers
Transaction under the Listing Rules: ANNOUNCEMENT - (1) COMPLETION OF VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER; (3) THE ONE-OFF SHARE OPTION PLAN; (4) CHANGE OF COMPANY NAME; (5) REMOVAL OF STOCK MARKER; (6) CHANGE IN THE COMPOSITION OF THE BOARD; (7) CHANGE OF AUTHORISED REPRESENTATIVES AND AGENT FOR THE SERVICES OF PROCESS IN HONG KONG; (8) CHANGE OF JOINT COMPANY SECRETARIES AND (9)CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG. Source
Dec 22, 2025Mergers
Transaction under the Listing Rules: ANNOUNCEMENT ON (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 22 DECEMBER 2025; (2) GRANT OF WHITEWASH WAIVER AND CONSENT TO SPECIAL DEAL; AND (3) INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY. Source
Dec 4, 2025Mergers
Transaction under the Listing Rules: (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN; AND DESPATCH OF CIRCULAR. Source
Dec 4, 2025Mergers
Transaction under the Listing Rules: (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL IN RELATION TO THE RETENTION PLAN OF THE SHAREHOLDER PERSONNEL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN; AND (8) NOTICE OF EGM. Source
Nov 27, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN; AND DELAY IN DESPATCH OF CIRCULAR. Source
Oct 27, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN; AND DELAY IN DESPATCH OF CIRCULAR. Source
Sep 25, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Aug 25, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Jul 25, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Jun 26, 2025Mergers
Transaction under the Listing Rules: FURTHER DELAY IN DESPATCH OF THE CIRCULAR IN RELATION TO - (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Jun 13, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
May 14, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Apr 15, 2025Mergers
Transaction under the Listing Rules: FILING OF THE NEW LISTING APPLICATION. Source
Mar 24, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Feb 25, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN; AND DELAY IN DESPATCH OF CIRCULAR. Source
Jan 24, 2025Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN; AND BUSINESS UPDATE. Source
Dec 27, 2024Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Nov 28, 2024Mergers
Transaction under the Listing Rules: MONTHLY UPDATE ON (1) VERY SUBSTANTIAL ACQUISITION INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE; (2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION; (3) APPLICATION FOR WHITEWASH WAIVER; (4) SPECIAL DEAL; (5) PROPOSED CHANGE OF COMPANY NAME; (6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND (7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN. Source
Nov 26, 2024Mergers
Transaction under the Listing Rules: APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER. Source

Press releases

Headlines of Edding Genor Group Holdings's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 23, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - FIRST-IN-HUMAN PHASE I STUDY DATA OF GB268 PRESENTED AT THE ESMO CONGRESS 2026
Oct 11, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - IND APPROVAL FROM THE NMPA FOR PHASE II CLINICAL TRIAL OF GB268 IN COLORECTAL CANCER
Aug 31, 2026HKEXnews
SHARE INCREASING PLAN BY THE CHAIRMAN OF THE BOARD AND ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE
Aug 28, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
Aug 21, 2026HKEXnews
PROFIT WARNING
Aug 6, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE FIRST SUBJECT DOSING IN PHASE IB/II CLINICAL TRIAL OF GB268
Aug 5, 2026HKEXnews
UPDATE ON CONTINUING CONNECTED TRANSACTION IN RELATION TO THE SUB-LICENSING ARRANGEMENT OF JING ZHU DA
Jul 16, 2026HKEXnews
DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN CANDID THERAPEUTICS, INC.
Jul 7, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE
Jul 2, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - PHASE IB/II CLINICAL TRIAL OF GB268 OBTAINED IND APPROVAL BY NMPA
Jun 26, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2026
Jun 10, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - SHARE INCREASING PLAN BY THE CHAIRMAN OF THE BOARD
May 13, 2026HKEXnews
CHANGE OF JOINT COMPANY SECRETARY
May 4, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON COOPERATION WITH CANDID THERAPEUTICS
Apr 15, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Mar 27, 2026HKEXnews
(1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025; (2) CHANGE OF EXECUTIVE DIRECTOR; AND (3) CHANGE OF CHIEF EXECUTIVE OFFICER
Mar 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - LATEST UPDATE ON COOPERATION WITH NANOPEPTIDE
Feb 9, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE FIRST SUBJECT DOSING IN PHASE II CLINICAL TRIAL OF EDP167
Feb 3, 2026HKEXnews
CHANGE OF COMPANY NAME AND STOCK SHORT NAME
Jan 22, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE UNDER THE REPURCHASE MANDATE

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6998 on TradingView.

Listing details

Company: Edding Genor Group Holdings Limited
Ticker: 6998
Listing: HKEX
Country or territory: China
Business scope: Biotechnology
ISIN: KYG3871A1004
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction